NOWDx Submits De Novo Classification Request to the FDA for OTC Syphilis Test
NOWDiagnostics submitted a De Novo Classification Request to the U.S. FDA for the company’s First to Know at-home syphilis test.
Read MorePosted by Andy Lundin | Jan 9, 2024 | Point-of-Care, Sexually Transmitted Diseases |
NOWDiagnostics submitted a De Novo Classification Request to the U.S. FDA for the company’s First to Know at-home syphilis test.
Read MorePosted by Andy Lundin | Jan 9, 2024 | Diagnostic Technologies |
Picodya, the creator of a hybrid IVD solution for multiplexed POC testing, announced the deployment of its B-Matrix technology in NIH labs.
Read MorePosted by Andy Lundin | Jan 5, 2024 | Lung Cancer |
The diagnostic, which requires only a simple urine test to read the results, could make lung cancer screening more accessible worldwide.
Read MorePosted by Andy Lundin | Jan 3, 2024 | Covid 19, POC Rapid Assays |
Sekisui formalized an exclusive distribution agreement with Aptitude Medical Systems to sell the Aptitude Metrix COVID Test in the U.S.
Read MorePosted by Andy Lundin | Jan 2, 2024 | Diagnostic Technologies |
Daxor submitted its next-generation blood volume analyzer—Daxor BVA—to the U.S. FDA via the 510(k)/CLIA-waiver dual submission pathway.
Read More